

What is claimed is:

1. A method for treating atopic dermatitis (AD) or improving an AD-associated parameter in a subject, the method comprising:
 - (a) selecting a subject with moderate-to-severe or severe AD that is not adequately controlled by topical AD medications, wherein the subject is ≥ 6 months to < 6 years of age; and
 - (b) administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.
2. The method of claim 1, wherein the subject is a subject with severe AD.
3. The method of claim 1 or 2, wherein the subject is inadequately responsive to treatment with a topical corticosteroid (TCS) of medium or higher potency.
4. The method of any one of claims 1 to 3, wherein the subject previously was administered a systemic AD medication.
5. The method of any one of claims 1 to 4, wherein the subject is aged ≥ 6 months to < 2 years.
6. The method of any one of claims 1 to 4, wherein the subject is aged ≥ 2 to < 6 years.
7. The method of any one of claims 1 to 6, wherein the subject:
 - (i) has a baseline Investigator's Global Assessment (IGA) score = 4;
 - (ii) has a baseline Eczema Area and Severity Index (EASI) score ≥ 21 ; and/or
 - (iii) has a baseline Body Surface Area (BSA) affected by AD $\geq 15\%$.
8. The method of any one of claims 1 to 7, wherein the IL-4R antagonist is subcutaneously administered at a dose of 3 mg/kg.
9. The method of any one of claims 1 to 7, wherein the IL-4R antagonist is subcutaneously administered at a dose of at least 6 mg/kg.
10. The method of claim 9, wherein the IL-4R antagonist is subcutaneously administered at a dose of 6 mg/kg.

11. The method of any one of claims 1 to 7, wherein the IL-4R antagonist is subcutaneously administered in an amount that results in a total exposure to the IL-4R antagonist in the subject of at least 130 day·mg/L.
12. The method of any one of claims 1 to 11, wherein the method comprises administering multiple doses of the IL-4R antagonist to the subject.
13. The method of claim 12, wherein the IL-4R antagonist is subcutaneously administered in an amount that results in a total exposure to the IL-4R antagonist in the subject of at least 130 day·mg/L for a period of at least two weeks.
14. The method of any one of claims 1 to 13, wherein the IL-4R antagonist is administered to the subject once a week or once every two weeks.
15. The method of any one of claims 1 to 14, wherein the subject has a concurrent atopic or allergic condition selected from the group consisting of allergic rhinitis, asthma, food allergy, allergic conjunctivitis, hives, chronic rhinosinusitis, nasal polyps, and eosinophilic esophagitis.
16. The method of claim 15, wherein the subject has a food allergy.
17. The method of any of claims 1 to 16, wherein the IL-4R antagonist is administered in combination with a topical AD medication.
18. The method of claim 17, wherein the topical AD medication is a medium-potency TCS or a low-potency TCS.
19. The method of any one of claims 1 to 18, wherein treatment with the IL-4R antagonist results in a reduction in the level of one or more type 2 inflammatory biomarkers in the subject relative to a baseline value.
20. The method of claim 19, wherein treatment with the IL-4R antagonist results in a reduction in the level of serum TARC and/or serum total IgE in the subject relative to a baseline value.
21. The method of any one of claims 1 to 20, wherein treatment with the IL-4R antagonist results in an improvement of one or more AD-associated parameters selected from:
 - (i) a reduction from baseline in IGA score to achieve an IGA score of 0 or 1 by week 4 after administration of the first dose of the IL-4R antagonist;
 - (ii) a reduction of at least 50% from baseline in an EASI score (EASI-50) by week 3 after administration of the first dose of the IL-4R antagonist;
 - (iii) a reduction of at least 75% from baseline in an EASI score (EASI-75) by week 3 after administration of the first dose of the IL-4R antagonist;

(iv) a reduction in percentage of BSA affected by AD to less than 40% of BSA by week 3 after administration of the first dose of the IL-4R antagonist; and

(v) a reduction of at 35% from baseline in BSA affected by AD by week 3 after administration of the first dose of the IL-4R antagonist.

22. The method of any one of claims 1 to 21, wherein the AD-associated parameter is determined based on a caregiver reported assessment.

23. The method of any one of claims 1 to 22, wherein treatment with the IL-4R antagonist results in an improvement in caregiver reported peak pruritus numerical rating scale (NRS) score.

24. The method of any one of claims 1 to 23, wherein treatment with the IL-4R antagonist results in an improvement in itch.

25. The method of claim 24, wherein the improvement in itch is assessed by caregiver reported peak pruritus NRS score.

26. The method of any one of claims 1 to 25, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.

27. The method of any one of claims 1 to 26, wherein the anti-IL-4R antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

28. The method of any one of claims 1 to 27, wherein the IL-4R antagonist is dupilumab or a bioequivalent thereof.

29. The method of any one of claims 1 to 28, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, a pen delivery device, and an autoinjector.

30. The method of claim 29, wherein the IL-4R antagonist is contained in a pre-filled syringe.

31. The method of claim 30, wherein the pre-filled syringe is a single-dose pre-filled syringe.

32. The method of claim 29, wherein the IL-4R antagonist is contained in an autoinjector.

33. The method of claim 29, wherein the IL-4R antagonist is contained in a pen delivery device.